Develop a US market access landscape in a rare disease to support commercial decision making and forecast assumptions
A large biopharmaceutical company required insight on the current market access landscape in a rare disease, as well as feedback on a pipeline product that will launch as a second-to-market agent in the rare disease.
Certara designed primary research with US payers to understand the rare disease market in three ways:
Today’s access landscape
Future access landscape with one new product launching
Future access landscape with two new products launching
Certara designed primary research with US payers to understand the rare disease market
Certara delivered a comprehensive report outlining favorable access for the pipeline product at a price above current standard of care’s wholesale acquisition cost (WAC), and identified endpoints that a second-to-market product could leverage to differentiate from the first-to-market product.